Author: Arabi, Yaseen M.; Asiri, Ayed Y.; Assiri, Abdullah M.; Aziz Jokhdar, Hani A.; Alothman, Adel; Balkhy, Hanan H.; AlJohani, Sameera; Al Harbi, Shmeylan; Kojan, Suleiman; Al Jeraisy, Majed; Deeb, Ahmad M.; Memish, Ziad A.; Ghazal, Sameeh; Al Faraj, Sarah; Al-Hameed, Fahad; AlSaedi, Asim; Mandourah, Yasser; Al Mekhlafi, Ghaleb A.; Sherbeeni, Nisreen Murad; Elzein, Fatehi Elnour; Almotairi, Abdullah; Al Bshabshe, Ali; Kharaba, Ayman; Jose, Jesna; Al Harthy, Abdulrahman; Al Sulaiman, Mohammed; Mady, Ahmed; Fowler, Robert A.; Hayden, Frederick G.; Al-Dawood, Abdulaziz; Abdelzaher, Mohamed; Bajhmom, Wail; Hussein, Mohamed A.
Title: Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-ß1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial Document date: 2020_1_3
ID: 0cah15lg_30
Snippet: The number and percentage of adverse events graded using the Common Terminology Criteria for Adverse Events, at any time within 28 days after enrollment. The adverse drug reactions include: allergic reactions, gastrointestinal, general nervous system and others. See also Table S6 Functional outcomes Karnofsky score Karnofsky Performance Status Scale for functional impairment, which is a scale from 100 (indicating "Normal," no complaints; no evide.....
Document: The number and percentage of adverse events graded using the Common Terminology Criteria for Adverse Events, at any time within 28 days after enrollment. The adverse drug reactions include: allergic reactions, gastrointestinal, general nervous system and others. See also Table S6 Functional outcomes Karnofsky score Karnofsky Performance Status Scale for functional impairment, which is a scale from 100 (indicating "Normal," no complaints; no evidence of disease) to 0 (indicating death) at day 90 outcome that accounts for the recursive design, as described in Chang [4] .
Search related documents:
Co phrase search for related documents- adverse drug reaction and drug reaction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- adverse event and allergic reaction: 1, 2, 3, 4
- adverse event and Common Terminology Criteria: 1, 2, 3, 4, 5, 6
- adverse event and disease evidence: 1, 2, 3, 4, 5
- adverse event and drug reaction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- adverse event and functional impairment: 1, 2, 3, 4
- adverse event and Functional outcome: 1, 2, 3, 4
- adverse event and general nervous system: 1
- adverse event and Karnofsky score: 1
- adverse event and nervous system: 1, 2, 3, 4, 5, 6
- adverse event and percentage number: 1, 2
- allergic reaction and drug reaction: 1, 2
- Common Terminology Criteria and disease evidence: 1
- Common Terminology Criteria and Karnofsky score: 1
- disease evidence and Functional outcome: 1
- disease evidence and Karnofsky score: 1
- disease evidence and nervous system: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- disease evidence and percentage number: 1, 2
- functional impairment and nervous system: 1, 2, 3, 4, 5
Co phrase search for related documents, hyperlinks ordered by date